Alpha Hope, via Molecular Hydrogen and Pyrroloquinoline Quinone, Dose-Dependently Increases Nrf2 and PGC-1α Levels in C2C12 Myoblasts
Richard J. Bloomer, Yufeng Zhang, Joshua Y. Shirazi, Chidimma Okegbe, Jacquelyn Pence, Keith Martin, Judi Q. Timmcke, Tyler W. LeBaron · Processes · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In participants, treatment significantly increased Nrf-2 and PGC-1α protein levels in C2C12 myoblasts, with no change for CS. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen was evaluated in this publication and summarizes the source-grounded findings below. Treatment significantly increased Nrf-2 and PGC-1α protein levels in C2C12 myoblasts, with no change for CS.
What the Researchers Studied
The study used a human clinical study. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Alpha Hope is a dietary supplement containing pyrroloquinoline quinone and elemental magnesium, which produces molecular hydrogen (H₂ gas) when dissolved in water. Treatment significantly increased Nrf-2 and PGC-1α protein levels in C2C12 myoblasts, with no change for CS.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The study used a human clinical study.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://www.mdpi.com/2227-9717/11/7/2011/pdf.